Highlights of SynBioBeta Day 2: Neobiological revolution, bio is not another app, living medicines, and biosecurity
Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)
News Digest #231 – New chemicals and materials report, living medicines, P&G embraces the biobased future (sponsored by P&G)
Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria
